|
|
|
|
Generic Names of Some Trade Name Drugs, THE MERCK MANUAL OF HEALTH & AGING
Committed to Providing Medical Information Table of Contents Index Enlarge Text Reset Text Shrink Text -- Buy the Book Learn about participating in clinical trials at this government website: www.clinicaltrials.gov - APPENDIX I - Drug Names: Generic and Trade TOPICS - Introduction -~ Some Trade Names of Generic Drugs -~ Generic Names of Some Trade Name Drugs - Generic Names of Some...
|
|
|
Some Trade Names of Generic Drugs, THE MERCK MANUAL OF HEALTH & AGING
Committed to Providing Medical Information Table of Contents Index Enlarge Text Reset Text Shrink Text -- Buy the Book Learn about participating in clinical trials at this government website: www.clinicaltrials.gov - APPENDIX I - Drug Names: Generic and Trade TOPICS - Introduction -~ Some Trade Names of Generic Drugs-~ Generic Names of Some Trade Name Drugs - Some Trade Names of...
|
|
|
http://www.fda.gov/cder/orange/appendix_a.txt
2, BUTABARBITAL SODIUM SARISOL, BUTABARBITAL SODIUM APPENDIX A PRODUCT NAME INDEX SATRIC, METRONIDAZOLE SCABENE, LINDANE SCANDONEST L, LEVONORDEFRIN SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE SCLEROSOL, TALC SCRUBTEAM SURGICAL SPONGEBRUSH, HEXACHLOROPHENE SEASONALE, ETHINYL ESTRADIOL SECOBARBITAL SODIUM, SECOBARBITAL SODIUM SECONAL SODIUM, SECOBARBITAL SODIUM SECREFLO, SECRETIN...
|
|
|
20-931_Tikosyn
Food and Drug Administration • Center for Drug Evaluation and Research Drug Information Search Tikosyn (Dofetilide) Capsules Company:--Pfizer Pharmaceutical Production Limited Application No.:--20-931 Approval Date:-10/1/1999 Approval Letter(s) - Printed Labeling - Medical Review(s)- Part 1 - Part 2 - Part 3 - Part 4 - Part 5 - Part 6 - Part 7 - Part 8 - Chemistry...
author: USERNAME
|
|
|
Report to the Nation: Drug Review
Priority new drug approvals: Alitretinoin Amprenavir (2 dosage forms) Aspirin/extended release-dipyridamole Bexarotene Busulfan Caffeine citrate Cytarabine liposome Dalfopristin/quinupristin Epirubicin hydrochloride Ganirelix acetate Ketotifen fumarate Levonorgestrel Nedocromil sodium Nitric oxide Orlistat Oseltamivir phosphate Pemirolast potassium Pioglitazone hydrochloride...
author: OLIVERN
|
|
|
NMEs Approved in CY 1999
NMEs Approved in Calendar Year 1999 NDA Number Generic Name- Trade Name Dosage Form Applicant - --- Classification- Approval Date - - - - - - - 20-863 Cilostazol Pletal Tablet Otsuka Pharm 1S 01-15-1999 20-886 Alitretinoin Panretin Topical Gel Ligand Pharm 1-PV 02-02-1999 20-955 Sodium Ferric Gluconate Complex Ferrlicit Injectable R&D Labs 1P 02-18-1999 21-007 Amprenavir Agenerase...
author: Elaine Abraham
|
|
|
Drugs with Required Restricted Distribution
Drugs with Required Restricted Distribution Clozapine (Clozaril?) Thalidomide (Thalomid?) Dofetilide (Tikosyn?) Mifepristone (Mifeprex?) Isotretinoin (Accutane?) Previous slide Next slide Back to first slide View graphic version Drugs with Required Restricted Distribution Drugs with Required Restricted Distribution
|
|
|
FDA Drug Approvals List- March 1999
Drug Approvals for March 1999 Definitions and Notes March 1999 Original New Drug Applications Original Application #: 020966 Approval Date: 30-MAR-99 Trade Name: SPORANOX Chemical Type: 3 Therapeutic Potential: S Dosage Form: INJECTABLE Applicant: JANSSEN RESEARCH FDN DIV JOHNSON AND JOHNSON Active Ingredient(s): ITRACONAZOLE OTC/RX Status: RX Indication(s): For the treatment of...
|
|
|
CDER 1999 Report to the Nation
1999 new molecular entities: Alitretinoin (Panretin) Aminolevulinic acid hydrochloride (Levulan Kerastick) Amprenavir (Agenerase) Bexarotene (Targretin) Cilostazol (Pletal) Dalfopristin/ quinupristin (Synercid) Dexmedetomidine hydrochloride (Precedex) Dofetilide (Tikosyn) Doxercalciferol (Hectorol) Entacapone (Comtan) Epirubicin hydrochloride (Ellence) Exemestane ...
author: Center for Drug Evaluation and Research
subject: Improving Public Health Through Human Drugs
|
|
|
CDER 1999 Report to the Nation page 12
author: Center for Drug Evaluation and Research
subject: Improving Public Health Through Human Drugs
|
|
|
CDER 1999 Report to the Nation page 11
author: Center for Drug Evaluation and Research
subject: Improving Public Health Through Human Drugs
|
|
|
Index D, THE MERCK MANUAL OF HEALTH & AGING
Committed to Providing Medical Information Table of Contents Index Enlarge Text Reset Text Shrink Text -- Buy the Book Learn about participating in clinical trials at this government website: www.clinicaltrials.gov - INDEX - Index-A -~ Index-B -~ Index-C -~ Index-D-~ Index-E -~ Index-F -~ Index-G -~ Index-H -~ Index-I -~ Index-J -~ Index-K -~ Index-L -~ Index-M -~ Index-N -~ Index-O ...
|
|
|
Microsoft PowerPoint - CV - Hamish Cameron.ppt
AstraZeneca Cardiovascular Hamish Cameron Vice President & Head of Cardiovascular TA Cancer Other and unknown causes Infectious and parasitic diseases Chronic obstructive lung diseases Injury and poisoning Maternal and perinatal causes Cardiovascular diseases Causes of death The burden of cardiovascular disease AstraZeneca Cardiovascular making the most of our marketed products...
author: m219594
duplicates:
http://www.astrazeneca.com/sites/7/imagebank/typeArticleparam11207/CV%20-%20Hamish%20Cameron.pdf
|
|
|
Microsoft PowerPoint - CV - Hamish Cameron.ppt page 25
author: m219594
duplicates:
http://www.astrazeneca.com/sites/7/imagebank/typeArticleparam11207/CV%20-%20Hamish%20Cameron.pdf
|
|
|
AstraZeneca Annual Business Review 2003-Pipeline Review
A AstraZeneca Annual Business Review October 2003 AZD0865 for Acid Related Diseases B Remaining unmet medical needs in ARD • Faster onset of action • Longer duration of action • Even better efficacy than Nexium ® • Less inter-patient variation B AZD0865 is a new class of compound • Different chemistry and mechanism than PPIs A AstraZeneca Annual Business...
|
|
|
AstraZeneca Annual Business Review 2003-Pipeline Review page 21
duplicates:
http://www.astrazeneca.com/sites/7/imagebank/typeArticleparam11180/Nicklasson3.pdf
|
|
|
BioPortfolio Limited
Atrial Fibrillation - Future Advances in Stroke Prevention TABLE OF CONTENTS CHAPTER 1 EXECUTIVE SUMMARY 3 Scope of the analysis 3 Datamonitor insight into the AF market 4 Key metrics 14 CHAPTER 2 INTRODUCTION AND SCOPE 23 Coverage of the Atrial Fibrillation Stakeholder Insight Survey 23 CHAPTER 3 COUNTRY TREATMENT TREES 26 Introduction to the treatment trees 26 US 27 Japan 30 France...
|
|
|
http://www.adis.com/files/newsletters/PEN/Pncov443.pdf
pylori infections: genotyping worth it in the US 7 Clobetasol foam enriches QOL in psoriasis 10 Abciximab value uncertain, stenting worth it 5 Levothyroxine plus liothyronine no aid to QOL in Antibacterial use for bacteraemia varies widely hypothyroidism 10 among ICUs 8 Methylphenidate combats fatigue, boosts QOL in Antidote availability improves after guideline cancer 10...
|
|
|
2000 International Users Meeting Abstracts & Presentations
NEWS EVENTS This year's international Users Meeting was a huge success, thanks to all of our presenters
This talk will focus on the strategies used in our group to screen orphan 7TM receptors for endogenous ligands on FLIPR using a combination of chimeric and promiscuous G proteins
The Cytosensor microphysiometer has been modified to directly measure the rate of lactate...
|
|
|
MDS_HERG_Whitepaper.qxd
High Throughput, Reliable, Cost- Effective Early Screening for Binding at the HERG Potassium Ion Channel The HERG potassium ion channel conducts rapidly activating delayed rectifier K + currents (Ikr ) that critically contribute to cardiac repolarization
Several amino acid residues (e
MDS Pharma Services' HERG binding assay is fully validated for rapid detection of HERG...
author: Mike
duplicates:
http://www.mdsps.com/solutions/whitepaper6.pdf
|
|
|
MDS_HERG_Whitepaper.qxd page 5
author: Mike
duplicates:
http://www.mdsps.com/solutions/whitepaper6.pdf
|
|
|
MDS_HERG_Whitepaper.qxd page 3
author: Mike
duplicates:
http://www.mdsps.com/solutions/whitepaper6.pdf
|
|
|
MDS_HERG_Whitepaper.qxd page 2
author: Mike
duplicates:
http://www.mdsps.com/solutions/whitepaper6.pdf
|
|
|
http://www.adis.com/files/newsletters/PEN/Pncov436.pdf
Also available in a choice of flexible electronic delivery options see back cover for details 1 Nov 2003 No
pylori treatment: costs in dyspepsia, peptic ulcer 9 ADHD: central stimulant use a burden in the US 10 Alternative medicine: WTP for increased regulation 7 Quality of Life Aspects Antibacterial use reduced in viral RTIs 9 Triamcinolone boosts QOL in perennial allergic...
|
|
|
http://www.adis.com/files/newsletters/INP/Icov1411.pdf
20 Ascorbic acid affects vasodilation in diabetes + CAD 19 Polio outbreak in southern Indian states 5 Aspirin ± clopidogrel: effects on platelet activity in CHF 19 US FDA guidance on use of animal drugs 4 Aspirin: evidence supports prevention of primary MI 16 Atherosclerosis vaccine increases HDL- cholesterol 11 MUSCULOSKELETAL Clopidogrel + aspirin inhibits platelet activity in...
|
